ClinicalTrials.gg
CompletedNCT02589600ZEST IIUpdated Sep 26, 2023Results posted

Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

A Phase 4 interventional study of Zoledronic acid and vitamin D in Osteoporotic Fractures and Osteoporosis, Postmenopausal, sponsored by Susan L. Greenspan. Completed at 1 site in United States. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-09-26.

Sponsored by Susan L. Greenspan · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
65 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Osteoporotic Fractures with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Osteoporotic Fractures · United States.

Started
2016
with 1 other
Phase 4
3 of 13
none open now
Registered
5th of 13
by date
Lead sponsor
3 of 13
Susan L. Greenspan

Among the 13 studies in Osteoporotic Fractures with a site in United States, this one is one of 2 that started in 2016, is one of 3 in phase 4, and was the 5th registered.

Osteoporotic Fractures

87 studies on the registry are indexed under Osteoporotic Fractures; 22 are open to participants now.

Browse Osteoporotic Fractures studies →

Open to participants now

2 of the 13 studies in Osteoporotic Fractures with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Osteoporotic Fractures studies recruiting now, 9 (64%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 65 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Osteoporotic Fractures with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to perform the first fracture reduction clinical trial with a potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term care population.

Read the detailed description

Although close to 85% of frail women in long-term care (LTC) facilities have osteoporosis and the risk of osteoporotic fractures is nearly 10 times that of community dwelling elderly, few are treated and studies are scarce. It is postulated that in frail, LTC women an annual infusion of zoledronic acid, an antiresorptive therapy for osteoporosis, will:

  1. be effective demonstrated by fracture reduction;
  2. be safe.

To address these hypotheses, up to 1000 female LTC residents age 65 and older will be screened in order to enroll 310 eligible for randomization in a 3 year, randomized, double-blind, calcium and vitamin D controlled trial with the antiresorptive agent zoledronic acid. Use of an intravenous, once yearly agent avoids concerns of oral bisphosphonate side effects, poor absorption and burden on staff. Participants will reside in the long-term care settings associated with the Division of Geriatric Medicine, University of Pittsburgh and will include women with multiple comorbid conditions, functional and cognitive impairment, and limited mobility.

03

Conditions studied

  • Osteoporotic Fractures
  • Osteoporosis, Postmenopausal

Keywords

  • Bone loss
  • Frail Geriatric Women
  • Nursing Home Patients
  • Long-term Care Patients
  • Osteoporosis
  • Osteoporotic Fractures
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women age ≥65 years including those using assistive devices to maximize generalizability if they:

    1. Reside in long-term care (LTC);
    2. Have:

      • osteoporosis by axial bone density (spine, hip or forearm bone mineral density (BMD) T-score ≤ -2.5 SD); or
      • a previous adult fragility fracture of the spine or hip; or,
      • would be treated based on FRAX National Osteoporosis Foundation (NOF) treatment thresholds of a 10 year risk of ≥ 20% for a major osteoporotic fracture or ≥ 3% for hip fracture using femoral neck BMD.

Exclusion criteria

Exclusion Criteria:

  • Men because osteoporosis is less common in men and our initial ZEST 1 study only included women.
  • Institutionalized women with subacute illnesses surviving or discharged in \< 3 years.
  • Women currently on bisphosphonate, denosumab, or teriparatide therapy or who have been on a bisphosphonate for greater than 1 year during the previous 2 years because bisphosphonates are long acting.
  • Patients with a calculated \< 35 ml/min or who have a for bisphosphonates (allergy, hypocalcemia).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    Active Medication Group

    Annual dose: intravenous zoledronic acid (Reclast) 5.0 mg; vitamin D (800 IU/daily) and calcium (approximately 1200 mg/daily, dietary + supplements)

    Drug: Zoledronic acid · Dietary Supplement: vitamin D · Dietary Supplement: calcium

  • Placebo comparator
    Placebo Group

    Annual dose: intravenous saline; vitamin D (800 IU/daily and calcium (approximately 1200 mg/daily, dietary + supplements)

    Dietary Supplement: vitamin D · Dietary Supplement: calcium · Other: Saline

Interventions

  • Annual intravenous 5.0 mg

    Also known as: Reclast

  • Dietary supplementvitamin D

    800 IU daily

  • Dietary supplementcalcium

    approximately 1200 mg (dietary and supplement)

  • OtherSaline

    Annual intravenous saline placebo

06

What researchers measure

Primary outcomes

  1. Non-traumatic Incidental Fractures (Vertebral and Nonvertebral [Identified by X-ray, CT, MRI, VFA Imaging] Per Person-year)

    Number of fractures divided by number of person-years. Effectiveness of fracture reduction will be demonstrated by total non-traumatic incidental fractures (vertebral and nonvertebral \[identified by x-ray, CT, MRI, VFA imaging) except those viewed as severe trauma (fall from a height higher than a stool or chair or severe trauma other than a fall), cancer-related or fractures of the toes, finger or facial bones.

    Time frame: 3 years

07

Results

Posted Aug 16, 2023

Participant flow

Recruitment will occur during the first 2 years of the grant cycle and take place in the determined long term care facilities.

Participant flow — Overall Study
MilestoneActive Medication GroupPlacebo Group
Started154156
Completed101102
Not completed5354

Outcome measures

PrimaryNon-traumatic Incidental Fractures (Vertebral and Nonvertebral [Identified by X-ray, CT, MRI, VFA Imaging] Per Person-year)

Number of fractures divided by number of person-years. Effectiveness of fracture reduction will be demonstrated by total non-traumatic incidental fractures (vertebral and nonvertebral \[identified by x-ray, CT, MRI, VFA imaging) except those viewed as severe trauma (fall from a height higher than a stool or chair or severe trauma other than a fall), cancer-related or fractures of the toes, finger or facial bones.

Time frame:
3 years
Reported as:
Number · Fractures per person-year
Non-traumatic Incidental Fractures (Vertebral and Nonvertebral [Identified by X-ray, CT, MRI, VFA Imaging] Per Person-year)
Fractures per person-yearActive Medication GroupPlacebo Group
Non-traumatic Incidental Fractures (Vertebral and Nonvertebral [Identified by X-ray, CT, MRI, VFA Imaging] Per Person-year)1.060931.01563
Statistical analysis
  • Active Medication Group vs Placebo Group · Negative binomial regression · p = 0.7251 · Incident rate ratio: 1.05 · 95% CI .90 to 1.22Placebo group is the reference group

Adverse events

Collected over Up to three years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Medication Group13/154 (8.4%)73/154 (47.4%)131/154 (85.1%)
Placebo Group19/156 (12.2%)80/156 (51.3%)130/156 (83.3%)
Most frequent serious events
Showing 10 of 139
Most frequent serious events
EventActive Medication GroupPlacebo Group
DeathGeneral disorders13/15419/156
FallInjury, poisoning and procedural complications9/1547/156
Chest painCardiac disorders8/1547/156
Urinary tract infectionRenal and urinary disorders4/1548/156
Hip fractureMusculoskeletal and connective tissue disorders6/1544/156
SyncopeNervous system disorders6/1542/156
Gastrointestinal hemorrhageGastrointestinal disorders5/1546/156
Atrial fibrillationCardiac disorders5/1545/156
Cardiac failure congestiveCardiac disorders5/1545/156
WeaknessGeneral disorders5/1540/156
Most frequent other events
Showing 10 of 16
Most frequent other events
EventActive Medication GroupPlacebo Group
FallInjury, poisoning and procedural complications59/15459/156
MyalgiaMusculoskeletal and connective tissue disorders31/15417/156
HeadacheNervous system disorders30/15418/156
NauseaGastrointestinal disorders22/15414/156
Influenza like illnessGeneral disorders22/1549/156
DiarrheaGastrointestinal disorders15/15418/156
Urinary tract infectionRenal and urinary disorders16/15417/156
FatigueGeneral disorders15/15410/156
ArthralgiaMusculoskeletal and connective tissue disorders14/15414/156
Back painMusculoskeletal and connective tissue disorders13/15411/156

Baseline characteristics

Same as participant flow

Age, Categorical
Age, Categorical(Participants)Active Medication GroupPlacebo GroupTotal
<=18 years000
Between 18 and 65 years000
>=65 years154156310
Age, Continuous
Age, Continuous(years)Active Medication GroupPlacebo GroupTotal
Mean81.3 ± 7.979.9 ± 7.780.6 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Active Medication GroupPlacebo GroupTotal
Female154156310
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active Medication GroupPlacebo GroupTotal
Hispanic or Latino314
Not Hispanic or Latino151155306
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active Medication GroupPlacebo GroupTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American111021
White142146288
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Active Medication GroupPlacebo GroupTotal
United States154156310
08

Study locations

1 site
  • University of Pittsburgh Osteoporosis Prevention & Treatment Center
    New Kensington, Pennsylvania 15068, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Jun 2022, 77 months.

Results were first posted in Aug 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2015
First posted
Oct 28, 2015
StartActual
Jan 2016
Primary completionActual
Jun 22, 2022
CompletionActual
Jun 22, 2022
Results first posted
Aug 16, 2023
Last update
Sep 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02589600
Lead sponsor
Susan L. Greenspan
Responsible party
Susan L. Greenspan (Professor of Medicine, University of Pittsburgh) — Sponsor-investigator
First posted
Oct 28, 2015
Start date
Jan 2016
Primary completion
Jun 22, 2022
Completion
Jun 22, 2022
Results posted
Aug 16, 2023
Last update
Sep 26, 2023

Study contacts

Susan L Greenspan, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zoledronic Acid

Start the discussion